Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours

Nat Commun. 2021 Mar 3;12(1):1407. doi: 10.1038/s41467-021-21675-6.

Abstract

Malignant rhabdoid tumour (MRT) is an often lethal childhood cancer that, like many paediatric tumours, is thought to arise from aberrant fetal development. The embryonic root and differentiation pathways underpinning MRT are not firmly established. Here, we study the origin of MRT by combining phylogenetic analyses and single-cell mRNA studies in patient-derived organoids. Comparison of somatic mutations shared between cancer and surrounding normal tissues places MRT in a lineage with neural crest-derived Schwann cells. Single-cell mRNA readouts of MRT differentiation, which we examine by reverting the genetic driver mutation underpinning MRT, SMARCB1 loss, suggest that cells are blocked en route to differentiating into mesenchyme. Quantitative transcriptional predictions indicate that combined HDAC and mTOR inhibition mimic MRT differentiation, which we confirm experimentally. Our study defines the developmental block of MRT and reveals potential differentiation therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation / genetics
  • DNA Methylation
  • Drug Screening Assays, Antitumor
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic / drug effects
  • Histone Deacetylase Inhibitors / pharmacology
  • Humans
  • Mutation*
  • Neural Crest / pathology
  • Phylogeny
  • Rhabdoid Tumor / drug therapy
  • Rhabdoid Tumor / genetics*
  • Rhabdoid Tumor / pathology*
  • SMARCB1 Protein / genetics
  • Single-Cell Analysis
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Tissue Culture Techniques / methods

Substances

  • Histone Deacetylase Inhibitors
  • SMARCB1 Protein
  • SMARCB1 protein, human
  • MTOR protein, human
  • TOR Serine-Threonine Kinases